Vivoryon Therapeutics NV Q4 2024 Earnings Call Transcript - Thomson StreetEvents

Vivoryon Therapeutics NV Q4 2024 Earnings Call Transcript

Vivoryon Therapeutics NV Q4 2024 Earnings Call Transcript - Thomson StreetEvents
Vivoryon Therapeutics NV Q4 2024 Earnings Call Transcript
Published Apr 29, 2025
12 pages (7644 words) — Published Apr 29, 2025
Price US$ 106.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of VVY.AS earnings conference call or presentation 29-Apr-25 1:00pm GMT

  
Brief Excerpt:

...Good afternoon, and thank you for joining us today to discuss the company's full-year 2024 results and operational updates. This morning Vivoryon issued a press release reporting its full-year 2024 financial results and also provided an update on our progress for the reporting period and year to date, which was marked by a strategic shift into kidney disease, creating a robust body of evidence for varoglutamstat's beneficial effect on kidney function as well as significant progress both on the preclinical and clinical front as well as on the corporate development side. This press release is posted on Vivoryon's website at www.vivoryon.com. On the call with me today are Vivoryon's Chief Executive Officer, Frank Weber; and our Chief Business Officer, Michael Schaeffer. I will begin today's call with an overview of the key highlights from the reporting year and post period updates and will then walk you through the financial results for 2024 and 2025 year to date, providing details on corporate...

  
Report Type:

Transcript

Source:
Company:
Vivoryon Therapeutics NV
Ticker
VVY.AS
Time
1:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Joseph Hedden - Rx Securities - Analyst : Congratulations on the IP and the new preclinical data. I guess I was just trying to dig in a little bit more onto any of the partnership discussions you may have been having recently. Maybe from the perspective of you've got this quite solid data in kidney disease now. You've compounded the preclinical package. The IP is important. You seem to be getting a lot of things in place. So I'm just wondering, is there anything else you see that a potential partner might be looking for that is still yet to come? Or do you now see yourself in a very solid position?


Question: Joseph Hedden - Rx Securities - Analyst : And then perhaps just one on the equity line. So you talk about it providing you more strategic flexibility. Are there any obvious wins perhaps that you -- anything left that you can kind of get the Phase 2b trial in a better position for? What's the position with the manufacturing of the drug product? Can you remind us, is there anything left over from the VIVIAD and VIVA-MIND programs? Or are you needing to run a manufacturing campaign for the next trial? And is that perhaps something this (inaudible) can help?


Question: Joseph Hedden - Rx Securities - Analyst : No, really, it was just on how might the equity line be used to get towards that Phase 2b trial?

Table Of Contents

Vivoryon Therapeutics NV to Host Virtual R and D Update with KOL Transcript – 2025-02-18 – US$ 54.00 – Edited Transcript of VVY.AS corporate analyst meeting</ 18-Feb-25 2:00pm GMT

Vivoryon Therapeutics NV Q3 2024 Earnings Call Transcript – 2024-12-10 – US$ 54.00 – Edited Transcript of VVY.AS earnings conference call or presentation 10-Dec-24 2:00pm GMT

Vivoryon Therapeutics NV Kidney Disease KOL Event (Virtual) Transcript – 2024-09-30 – US$ 54.00 – Edited Transcript of VVY.AS corporate analyst meeting</ 30-Sep-24 1:00pm GMT

Half Year 2024 Vivoryon Therapeutics NV Earnings Call Transcript – 2024-09-12 – US$ 54.00 – Edited Transcript of VVY.AS earnings conference call or presentation 12-Sep-24 1:00pm GMT

Vivoryon Therapeutics NV R and D Update Call Transcript – 2024-07-18 – US$ 54.00 – Edited Transcript of VVY.AS conference call or presentation 18-Jul-24 1:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Vivoryon Therapeutics NV Q4 2024 Earnings Call Transcript" Apr 29, 2025. Alacra Store. May 13, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2024-Vivoryon-Therapeutics-NV-Earnings-Call-T16327637>
  
APA:
Thomson StreetEvents. (2025). Vivoryon Therapeutics NV Q4 2024 Earnings Call Transcript Apr 29, 2025. New York, NY: Alacra Store. Retrieved May 13, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2024-Vivoryon-Therapeutics-NV-Earnings-Call-T16327637>
  
US$ 106.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.